


# ContraFect

## COMPANY OVERVIEW

ContraFect is a clinical stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. Our lysin and monoclonal antibody platforms target conserved regions of bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (methicillin resistant *Staph aureus*) and influenza.



## CONTRAFECT CORPORATION

28 Wells Avenue  
3rd Floor  
Yonkers, NY 10701  
US

## RECENT NEWS

**ContraFect to Present at Piper Jaffray Health Care Conference**  
Nov 19 2018, 7:00 AM EST

**ContraFect Appoints Michael Messinger as Chief Financial Officer**  
Nov 12 2018, 7:00 AM EST

**ContraFect Announces Third Quarter 2018 Financial Results**  
Nov 8 2018, 7:00 AM EST

## STOCK OVERVIEW

Symbol	CFRX
Exchange	Nasdaq
Market Cap	165.17m
Last Price	\$2.08
52-Week Range	\$0.90 - \$2.9266

12/14/2018 04:00 PM EST

## INVESTOR RELATIONS

Michael Messinger  
T: 914-207-2300  
[mmessinger@contrafect.com](mailto:mmessinger@contrafect.com)

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.